241 related articles for article (PubMed ID: 34193193)
1. Nomogram for short-term outcome assessment in AChR subtype generalized myasthenia gravis.
Zhao R; Wang Y; Huan X; Zhong H; Zhou Z; Xi J; Da Y; Lei L; Chang T; Ruan Z; Luo L; Li S; Yang H; Li Y; Luo S; Zhao C
J Transl Med; 2021 Jun; 19(1):285. PubMed ID: 34193193
[TBL] [Abstract][Full Text] [Related]
2. Constructing and Validating a Nomogram Model for Short-Term Prognosis of Patients with AChR-Ab+ GMG.
Liang F; Yin Z; Li Y; Li G; Ma J; Zhang H; Xia X; Yao M; Pang X; Wang J; Chang X; Guo J; Zhang W
Neurol Ther; 2024 Jun; 13(3):551-562. PubMed ID: 38427273
[TBL] [Abstract][Full Text] [Related]
3. Increased serum IL-2, IL-4, IL-5 and IL-12p70 levels in AChR subtype generalized myasthenia gravis.
Huan X; Zhao R; Song J; Zhong H; Su M; Yan C; Wang Y; Chen S; Zhou Z; Lu J; Xi J; Luo S; Zhao C
BMC Immunol; 2022 May; 23(1):26. PubMed ID: 35624411
[TBL] [Abstract][Full Text] [Related]
4. Factors affecting outcome in ocular myasthenia gravis.
Mazzoli M; Ariatti A; Valzania F; Kaleci S; Tondelli M; Nichelli PF; Galassi G
Int J Neurosci; 2018 Jan; 128(1):15-24. PubMed ID: 28625092
[TBL] [Abstract][Full Text] [Related]
5. Factors Affecting Generalization of Ocular Myasthenia Gravis in Patients With Positive Acetylcholine Receptor Antibody.
Apinyawasisuk S; Chongpison Y; Thitisaksakul C; Jariyakosol S
Am J Ophthalmol; 2020 Jan; 209():10-17. PubMed ID: 31562855
[TBL] [Abstract][Full Text] [Related]
6. Antibody profile may predict outcome in ocular myasthenia gravis.
Galassi G; Mazzoli M; Ariatti A; Kaleci S; Valzania F; Nichelli PF
Acta Neurol Belg; 2018 Sep; 118(3):435-443. PubMed ID: 29858757
[TBL] [Abstract][Full Text] [Related]
7. Minimal symptom expression achievement over time in generalized myasthenia gravis.
Uzawa A; Ozawa Y; Yasuda M; Onishi Y; Akamine H; Kuwabara S
Acta Neurol Belg; 2023 Jun; 123(3):979-982. PubMed ID: 36592291
[TBL] [Abstract][Full Text] [Related]
8. Clinical Utility of Acetylcholine Receptor Antibody Testing in Ocular Myasthenia Gravis.
Peeler CE; De Lott LB; Nagia L; Lemos J; Eggenberger ER; Cornblath WT
JAMA Neurol; 2015 Oct; 72(10):1170-4. PubMed ID: 26258604
[TBL] [Abstract][Full Text] [Related]
9. Adult Ocular Myasthenia Gravis Conversion: A Single-Center Retrospective Analysis in China.
Feng X; Huan X; Yan C; Song J; Lu J; Zhou L; Wu H; Qiao K; Lu J; Xi J; Luo S; Zhao C
Eur Neurol; 2020; 83(2):182-188. PubMed ID: 32526733
[TBL] [Abstract][Full Text] [Related]
10. Eye muscle antibodies in patients with ocular myasthenia gravis: possible mechanism for eye muscle inflammation in acetylcholine-receptor antibody-negative patients.
Gunji K; Skolnick C; Bednarczuk T; Benes S; Ackrell BA; Cochran B; Kennerdell JS; Wall JR
Clin Immunol Immunopathol; 1998 Jun; 87(3):276-81. PubMed ID: 9646837
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of detection of antibodies to fetal and adult acetylcholine receptors in myasthenia gravis.
Shi QG; Wang ZH; Ma XW; Zhang DQ; Yang CS; Shi FD; Yang L
Neurosci Bull; 2012 Oct; 28(5):469-74. PubMed ID: 22961471
[TBL] [Abstract][Full Text] [Related]
12. Efgartigimod and Ravulizumab for Treating Acetylcholine Receptor Auto-antibody-Positive (AChR-Ab+) Generalized Myasthenia Gravis: Indirect Treatment Comparison.
van Steen C; Celico L; Spaepen E; Hagenacker T; Meuth SG; Ruck T; Smith AG; Bodicoat DH; de Francesco M; Iannazzo S
Adv Ther; 2024 Jun; 41(6):2486-2499. PubMed ID: 38642198
[TBL] [Abstract][Full Text] [Related]
13. 'Minimal symptom expression' in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab.
Vissing J; Jacob S; Fujita KP; O'Brien F; Howard JF;
J Neurol; 2020 Jul; 267(7):1991-2001. PubMed ID: 32189108
[TBL] [Abstract][Full Text] [Related]
14. Nomogram for the acute exacerbation of acetylcholine receptor antibody-positive generalized myasthenia gravis.
Chen J; Li S; Feng L; Wang H; Huang X; Feng H
Neurol Sci; 2023 Mar; 44(3):1049-1057. PubMed ID: 36369308
[TBL] [Abstract][Full Text] [Related]
15. Clinical Experience with Eculizumab in Treatment-Refractory Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis.
Katyal N; Narula N; Govindarajan R
J Neuromuscul Dis; 2021; 8(2):287-294. PubMed ID: 33325394
[TBL] [Abstract][Full Text] [Related]
16. Significance of Acetylcholine Receptor Antibody Titers in Acetylcholine Receptor Antibody-Positive Ocular Myasthenia Gravis: Generalization and Presence of Thyroid Autoimmune Antibodies and Thymoma.
Supawongwattana M; Vanikieti K; Jindahra P; Padungkiatsagul T
Clin Ophthalmol; 2023; 17():649-656. PubMed ID: 36875532
[TBL] [Abstract][Full Text] [Related]
17. Development and Validation of a Nomogram for Predicting Generalization in Patients With Ocular Myasthenia Gravis.
Ruan Z; Sun C; Lang Y; Gao F; Guo R; Xu Q; Yu L; Wu S; Lei T; Liu Y; Zhang M; Li H; Tang Y; Gao T; Gao Y; Lu X; Li Z; Chang T
Front Immunol; 2022; 13():895007. PubMed ID: 35874731
[TBL] [Abstract][Full Text] [Related]
18. Ravulizumab: A Review in Generalised Myasthenia Gravis.
Kang C
Drugs; 2023 Jun; 83(8):717-723. PubMed ID: 37166620
[TBL] [Abstract][Full Text] [Related]
19. Prediction of the generalization of myasthenia gravis with purely ocular symptoms at onset: a multivariable model development and validation.
Li F; Zhang H; Tao Y; Stascheit F; Han J; Gao F; Liu H; Carmona-Bayonas A; Li Z; Rueckert JC; Meisel A; Zhao S
Ther Adv Neurol Disord; 2022; 15():17562864221104508. PubMed ID: 35755967
[TBL] [Abstract][Full Text] [Related]
20. Does change in acetylcholine receptor antibody level correlate with clinical change in myasthenia gravis?
Sanders DB; Burns TM; Cutter GR; Massey JM; Juel VC; Hobson-Webb L;
Muscle Nerve; 2014 Apr; 49(4):483-6. PubMed ID: 23835683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
